Clinical trial · Observational
Molecular Analysis and Treatment Options of Thymic Malignancies
Molecular Landscape Analysis and Treatment Options for Thymic Epithelial Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death. Therefore, there is an unmet need for more effective therapies for thymic malignancies. Considering the role of molecular alterations has yet to be defined in the treatment of thymoma and thymic malignancies, there is an urgent recognition that molecular alterations in the thymic malignancies are important to predict response and survival for novel targeted therapies. In summary, identification of genetic alterations in thymic malignancies is increasingly essential to perform molecular diagnostics and individualized treatments. This project aims to create a registry of patients with thymic malignancies to further the characterization of molecular alterations and develop (novel) treatments based on the detection.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thymic Cancer | — | UNRESOLVED | — |
| Thymic Carcinoma | Thymus Carcinoma | CURATED_BROADER | 0.80 |
| Thymic Epithelial Tumor | Thymus Epithelial Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Objective response rate (ORR)
- timeFrame
- 20 years
- description
- Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
- measure
- Disease control rate (DCR)
- timeFrame
- 20 years
- description
- Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
- measure
- Progression-free survival (PFS)
- timeFrame
- 20 years
- description
- Collect detailed clinical information on patients with thymic malignancies via the electronic medical records
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven diagnosis of thymic malignancies * 18 years of age or older * Ability to understand and the willingness to sign a written informed consent document
References
Publications (0)
Data not yet available